Avaxia Biologics, Inc. Announces First Patient Dosed in Phase 1b Study of AVX-470 in Ulcerative Colitis
2/25/2013 11:09:30 AM
More...
|
Avaxia Biologics, Inc. Raises $6.4 Million in Series B Financing
12/18/2012 6:44:10 AM
More...
|
Avaxia Biologics, Inc. Receives IND Clearance From FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
11/27/2012 8:29:47 AM
More...
|
Avaxia Biologics, Inc. is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
9/18/2012 10:15:25 AM
More...
|
Avaxia Biologics, Inc. Announces Appointment of Michael D. Rivard as VP Corporate Development
6/13/2012 10:09:49 AM
More...
|
Avaxia Biologics, Inc. is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
5/23/2012 9:43:53 AM
More...
|
Avaxia Biologics, Inc. Elects Christopher Kiritsy to its Board of Directors
4/26/2012 11:45:55 AM
More...
|
Avaxia Biologics, Inc. Awarded $1.5 Million Phase II SBIR Grant from NIH to Develop Oral Antibody Therapeutic for Inflammatory Bowel Disease
3/20/2012 8:46:35 AM
More...
|
Avaxia Biologics, Inc.'s Barbara Fox Named One of Mass High Tech's Women to Watch in 2012
3/1/2012 7:23:18 AM
More...
|
Courtagen Life Sciences, Inc. to Partner with Avaxia Biologics, Inc. in GI Acute Radiation Syndrome Initiative
2/29/2012 6:30:38 AM
More...
|
|